Clinical studies have demonstrated that the CHEK1 inhibitor AZD7762 synergizes with CDK4/6 inhibitors in HR+ breast cancer models, highlighting the potential of CHEK1 as a cross-subtype therapeutic target [71]. Here, CDK4 is linked to breast carcinoma.